Table A4.
Characteristics of patients firstly treated with CLI, DBS as second treatment—reported in literature.
| Faust-Socher et al., 2019 | Nathoo et al., 2019 | Nathoo et al., 2019 | Spanaki et al., 2020 | |
|---|---|---|---|---|
| Case | Case 1 | Case 1 | Case 2 | Combined data (n = 2) |
| Sex M:F | F | M | M | UA |
| Age at PD diagnosis in years; range (mean) | 29 | 45 | 56 | UA |
| Age at initiation first treatment in years; range (mean) | 37 | 57 | 64 | UA |
| Interval between initiation treatments in years; range (mean) | 8 | 2 | 2 | UA |
| Initial effect of first treatment | UA | Good | Good | UA |
| DBS target | R/L GPi | R/L STN | R/L GPi | STN |
| Initial therapy continued | UA | No | No | UA |
| Indication for second treatment | Dyskinesia, painful dystonia | MFD | MFD, dystonia | Levodopa induced symptoms |
| LEDD pre-CLI; range (mean) | UA | UA | UA | UA |
| LEDD post-CLI; range (mean) | 1179 | UA | UA | UA |
| UPDRS-III med off pre-DBS; range (mean) | 34 | 49 | 23 | UA |
| UPDRS -III med on pre-DBS; range (mean) | 19 | 32 | 22 | UA |
| Improvement according to authors | Yes | Yes | Yes | UA |
CLI: continuous levodopa/carbidopa infusion; DBS: deep drain stimulation; F: female; GPi: globus pallidus interna; LEDD: levodopa equivalent daily dose; M: male; med: medication; MF: unpredictable motor fluctuations; MFD: unpredictable motor fluctuations and dyskinesias; PD: Parkinson’s disease; R/L: right/left; STN: subthalamic nucleus; UA: unavailable; UPDRS: Unified Parkinson’s Disease Rating Scale, part III.